Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00017407 · ClinicalTrials.gov registry record · Phase 3
Carboplatin and Paclitaxel With or Without ISIS 3521 in Treating Patients With Non-Small Cell Lung Cancer
A Phase 3 study, sponsored by Ionis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
NCT00017407 is a Phase 3 study that has completed, run by Ionis Pharmaceuticals.
The verdict
NCT00017407, a Phase 3 study, has completed, sponsored by Ionis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. ISIS 3521 may help kill more cancer cells by making tumor cells more sensitive to chemotherapy. It is not yet known if carboplatin and paclitaxel are more effective with or without ISIS 3521. PURPOSE: Randomized phase III trial to compare the effectiveness of carboplatin and paclitaxel with or without ISIS 3521 in treating patients who have stage IIIB or stage IV non-small cell lung cancer.
Interventions
- DRUG carboplatin
- DRUG paclitaxel
- BIOLOGICAL ISIS 3521
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-10-13 |
| Est. Completion | 2002-09-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00017407
The ClinicalTrials.gov registry entry for NCT00017407 describes a study currently listed as completed, categorized as Phase 3. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Ionis Pharmaceuticals, which has 76 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which carboplatin is the first listed.
NCT00017407 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00017407 about?
NCT00017407 is a clinical study titled "Carboplatin and Paclitaxel With or Without ISIS 3521 in Treating Patients With Non-Small Cell Lung Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. ISIS 3521 may help kill more cancer cells by making tumor cells more sensitive to chemotherapy. It is not yet known if carboplatin and paclitaxel are more effective with or without...
What is the current status of trial NCT00017407?
This trial is currently completed. It is a Phase 3 study. The study started on 2000-10-13. Estimated completion is 2002-09-09.
What interventions are being tested in trial NCT00017407?
The interventions under investigation include: carboplatin (DRUG), paclitaxel (DRUG), ISIS 3521 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00017407?
This trial is sponsored by Ionis Pharmaceuticals, which has 76 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.